#1 Clinical Trials Search in Europe

FRUQUINTINIB

Fruquintinib is an innovative oral medication being studied in numerous clinical trials for its potential to treat various types of cancer. As a selective tyrosine kinase inhibitor (TKI), fruquintinib specifically targets vascular endothelial growth factor receptors (VEGFR-1, -2, and -3), which play crucial roles in tumor blood vessel formation. This targeted approach allows fruquintinib to potentially block the blood supply to tumors, slowing or stopping their growth. Clinical trials are exploring fruquintinib’s effectiveness both as a standalone treatment and in combination with other cancer therapies, particularly for patients with metastatic colorectal cancer and other solid tumors. This article summarizes the current landscape of fruquintinib clinical trials, their findings, and what patients might expect when participating in these studies.

Table of Contents

What is Fruquintinib?

Fruquintinib (also known by the brand name Fruzaqla™ or HMPL-013) is a novel oral medication classified as a tyrosine kinase inhibitor (TKI) [1]. It was specifically designed to target proteins called vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3) [2]. What makes fruquintinib special is its high selectivity for these specific receptors, which helps reduce unwanted effects on other bodily systems.

Fruquintinib belongs to the quinazoline class of drugs and has a unique chemical structure that distinguishes it from other medications in the same category [2]. This medication has shown promising results in clinical trials, particularly for patients with colorectal cancer who have already received other treatments.

How Does Fruquintinib Work?

To understand how fruquintinib works, it’s helpful to know about a process called angiogenesis. Angiogenesis is the formation of new blood vessels, which is a normal process in growth and healing. However, cancer cells can hijack this process to create their own blood supply, allowing tumors to grow and spread.

Fruquintinib works by blocking the action of VEGFR-1, VEGFR-2, and VEGFR-3, which are proteins that play a key role in angiogenesis [2]. By inhibiting these receptors, fruquintinib helps cut off the blood supply to tumors, potentially slowing or stopping their growth.

Unlike some other medications, fruquintinib has minimal metabolism by liver enzymes, which may give it advantages in terms of drug interactions and effectiveness [3].

Conditions Treated with Fruquintinib

Fruquintinib has been most extensively studied in metastatic colorectal cancer (mCRC), particularly in patients who have already undergone standard treatments like fluorouracil, oxaliplatin, and irinotecan-based therapies [4]. Clinical trials have shown promising results in this patient population, leading to its approval for use in some countries.

Beyond colorectal cancer, fruquintinib is being investigated for several other cancer types, including:

  • Advanced solid tumors of various types [2]
  • Metastatic breast cancer, including hormone receptor-positive, HER2-negative, and triple-negative subtypes [2]
  • Non-small cell lung cancer (NSCLC) [5]
  • Gastric (stomach) cancer [6]
  • Hepatocellular carcinoma (liver cancer) [7]
  • Renal cell carcinoma (kidney cancer) [8]
  • Biliary tract adenocarcinoma (cancer of the bile ducts) [9]
  • Pancreatic cancer [10]
  • Soft tissue sarcomas [11]

Dosage and Administration

Fruquintinib is an oral medication that comes in capsule form, typically available in strengths of 1 mg and 5 mg [1]. Based on clinical trials, the most common dosing regimen is 5 mg once daily, taken for 3 weeks followed by a 1-week break (known as a 3/1 schedule) [4]. This 4-week period is considered one treatment cycle.

Some specific dosing patterns that have been studied include:

  • 5 mg once daily for 21 days, followed by 7 days off [4]
  • 4 mg once daily for 21 days, followed by 7 days off [5]
  • 3 mg once daily continuously [12]
  • In some studies, a 5 mg dose taken for 2 weeks on/1 week off has also been investigated [8]

For elderly patients or those with specific health concerns, dose optimization strategies may be employed. One approach starts with a lower dose (3 mg daily) in the first week, potentially increasing to 4 mg in the second week and 5 mg in the third week if well tolerated [13].

Fruquintinib can be taken with or without food, although studies have examined how food might affect how the drug is absorbed by your body [14].

Efficacy of Fruquintinib

Clinical trials have demonstrated the effectiveness of fruquintinib in several cancer types, with the most robust evidence in metastatic colorectal cancer.

In patients with metastatic colorectal cancer who had already received standard treatments, fruquintinib has shown significant benefits compared to placebo:

  • Improved overall survival: Patients receiving fruquintinib lived longer (median overall survival of 9.3 months versus 6.6 months with placebo) [7]
  • Extended progression-free survival: The time before the cancer started growing again was longer with fruquintinib (median progression-free survival of 3.7 months versus 1.8 months with placebo) [7]
  • Disease control rate: Studies have shown that fruquintinib can help control cancer growth in a significant percentage of patients [4]

For other cancer types, research is still ongoing, but early studies suggest potential benefits in various solid tumors [2].

In combination therapies, fruquintinib plus immune checkpoint inhibitors (like sintilimab) has shown promising activity in hepatocellular carcinoma, with a reported tumor response rate of 31.6% and a median progression-free survival of 7.4 months [7].

Potential Side Effects

Like all medications, fruquintinib can cause side effects. Common side effects that have been reported in clinical trials include:

  • Hypertension (high blood pressure) – This is one of the most common side effects and requires monitoring [15]
  • Hand-foot syndrome (palmar-plantar erythrodysesthesia) – This can cause redness, swelling, and pain on the palms of the hands and soles of the feet [15]
  • Proteinuria – Protein in the urine, which may indicate kidney effects [1]
  • Fatigue – Feeling unusually tired or weak [4]
  • Diarrhea [4]
  • Decreased appetite [4]
  • Oral mucositis – Inflammation of the mucous membranes lining the mouth [4]
  • Thyroid dysfunction [4]
  • Elevated liver enzymes [4]

Most side effects are manageable with proper monitoring and dose adjustments if necessary. Your healthcare team will work with you to manage any side effects that occur during treatment.

Ongoing Research and Future Applications

Fruquintinib is being actively studied in numerous clinical trials across different cancer types and treatment scenarios. Some key areas of ongoing research include:

  • Combination therapies: Studies are exploring the combination of fruquintinib with other anti-cancer treatments, including:
    • Chemotherapy regimens like FOLFOX and FOLFIRI [16]
    • Immune checkpoint inhibitors such as sintilimab [12]
    • Other targeted therapies [17]
  • Earlier treatment lines: While fruquintinib has primarily been studied in patients who have already received multiple treatments, research is now exploring its use in earlier treatment settings, including first-line and maintenance therapy [18]
  • Expanded cancer types: Research continues to investigate fruquintinib’s potential in a wider range of cancer types [2]
  • Special populations: Studies are addressing how fruquintinib can be optimally used in specific patient groups, such as elderly patients or those with liver or kidney impairment [13] [19] [20]

One particularly interesting area of research is the use of fruquintinib as a maintenance therapy after successful initial treatment. For example, studies are looking at its potential to reduce recurrence in colorectal cancer patients who have achieved “no evidence of disease” (NED) status after treatment for liver metastases [21].

Practical Considerations for Patients

If you’re considering or already taking fruquintinib, here are some practical points to keep in mind:

  • Regular monitoring: Your healthcare team will likely schedule regular check-ups to monitor your blood pressure, kidney function, liver function, and other important health parameters [4]
  • Medication schedule: It’s important to take fruquintinib exactly as prescribed, including following the on-treatment and off-treatment periods if your dosing regimen includes breaks [4]
  • Drug interactions: Inform your healthcare provider about all other medications you’re taking, including over-the-counter drugs, supplements, and herbal remedies. Studies have looked at interactions with certain medications like proton pump inhibitors (medications for acid reflux) [22]
  • Lifestyle considerations: Your doctor may recommend monitoring your diet, particularly around the time you take the medication. Some studies have examined whether taking fruquintinib with or without food affects how well it works [14]
  • Clinical trials: If you’re interested in fruquintinib but it’s not yet approved for your specific condition, ask your healthcare provider about clinical trials that might be appropriate for you [2]

Remember that fruquintinib is a relatively new medication, and research continues to evolve. Stay in close communication with your healthcare team about the latest information and how it might apply to your individual situation.

Cancer Type Trial Phase Treatment Approach Key Findings
Metastatic Colorectal Cancer (mCRC) Phase II/III Fruquintinib monotherapy; Fruquintinib + chemotherapy (FOLFOX/FOLFIRI); Fruquintinib vs. Bevacizumab Most advanced research area; Improved PFS and OS in refractory mCRC compared to placebo in FRESCO and FRESCO-2 trials; ULYSSE trial ongoing to compare with bevacizumab
Advanced Solid Tumors Phase I/II Dose escalation studies (3mg, 4mg, 5mg); Various dosing schedules Established MTD and dosing schedules; Well-tolerated with manageable safety profile; Common dosing: 5mg once daily, 3 weeks on/1 week off
Metastatic Breast Cancer Phase I/II Hormone receptor positive/HER2-negative; Triple-negative breast cancer Specific cohorts in multi-center trials; Preliminary efficacy signals being investigated
Hepatocellular Carcinoma Phase II After immune checkpoint inhibitor failure Investigating fruquintinib as second-line treatment; Anti-angiogenic approach may benefit patients who progressed on immunotherapy
Sarcomas Phase II Various soft tissue and bone sarcomas Studies in chemotherapy-insensitive or resistant sarcomas; Alternative for patients with limited treatment options
Special Populations Phase I/IV Elderly patients; Patients with hepatic or renal impairment; Minority populations Dose optimization studies for elderly patients (starting at lower doses); Modified dosing for organ dysfunction; Safety monitoring in underrepresented populations
Combinations with Immunotherapy Phase Ib/II Fruquintinib + immune checkpoint inhibitors (e.g., sintilimab) Exploring potential synergistic effects; May enhance immune response against tumors
Common Side Effects All phases Safety assessments Hypertension, hand-foot syndrome, fatigue, diarrhea, proteinuria, decreased appetite; Most manageable with dose adjustments or supportive care

FAQ

  • What is fruquintinib and how does it work? Fruquintinib is a novel oral medication classified as a tyrosine kinase inhibitor (TKI) that selectively targets vascular endothelial growth factor receptors (VEGFR-1, -2, and -3). These receptors are important for the formation of new blood vessels that feed tumors. By blocking these receptors, fruquintinib works to cut off the blood supply to cancer cells, potentially slowing or stopping tumor growth. Unlike some other medications in its class, fruquintinib has a unique chemical structure belonging to the quinazoline class and shows high selectivity for its targets.
  • For which types of cancer is fruquintinib being studied? Fruquintinib is being studied across multiple cancer types. The most advanced research is in metastatic colorectal cancer (mCRC), particularly in patients who have already tried standard treatments. Other cancer types being investigated include advanced solid tumors, metastatic breast cancer (including triple-negative and hormone receptor positive types), gastric cancer, biliary tract cancer, hepatocellular carcinoma (liver cancer), renal cell carcinoma (kidney cancer), pancreatic cancer, and various types of sarcomas (bone and soft tissue cancers).
  • What are the common dosing schedules for fruquintinib in clinical trials? In most clinical trials, fruquintinib is typically administered in one of several dosing schedules. The most common regimen is 5 mg taken orally once daily for 3 weeks, followed by a 1-week break (3 weeks on/1 week off in a 28-day cycle). Some trials also explore 4 mg daily dosing or different schedules such as 2 weeks on/1 week off in a 21-day cycle. For elderly patients or those with certain health conditions, trials may start with lower doses (3 mg) and gradually increase if well tolerated. The specific dosing schedule depends on the particular trial protocol and may be adjusted based on how patients respond to treatment.
  • What are the most common side effects of fruquintinib? Common side effects observed in fruquintinib clinical trials include hypertension (high blood pressure), hand-foot syndrome (also called palmar-plantar erythrodysesthesia, causing redness, swelling, and pain in hands and feet), fatigue, diarrhea, decreased appetite, and proteinuria (protein in urine). Some patients may also experience liver function abnormalities, reduced blood cell counts, voice changes (dysphonia), and thyroid dysfunction. Most side effects can be managed with dose adjustments or supportive care. Serious side effects are less common but may include severe bleeding or blood clots. The specific safety profile may vary depending on whether fruquintinib is used alone or in combination with other treatments.
  • How does fruquintinib compare to other treatments for metastatic colorectal cancer? In clinical trials for metastatic colorectal cancer, fruquintinib has shown promise compared to placebo in patients who have failed standard treatments. For example, the FRESCO and FRESCO-2 trials demonstrated improved progression-free survival and overall survival with fruquintinib compared to placebo. Some ongoing trials are comparing fruquintinib plus chemotherapy (like FOLFOX or FOLFIRI) to standard treatments including bevacizumab combinations. The ULYSSE trial is specifically comparing fruquintinib to bevacizumab when combined with chemotherapy in second-line treatment. Other studies are exploring fruquintinib combined with raltitrexed or immune checkpoint inhibitors. Each approach may offer different benefits and side effect profiles, and the optimal sequencing of these treatments is still being determined through clinical research.

Ongoing Clinical Trials on FRUQUINTINIB

  • A study comparing trifluridine, tipiracil, and fruquintinib versus trifluridine and tipiracil alone for patients with metastatic stomach or esophageal cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Spain

  • Study of FOLFOX or FOLFIRI chemotherapy with fruquintinib or bevacizumab as second-line treatment for patients with metastatic colorectal cancer

    Recruiting

    1 1 1
    Investigated drugs:
    France

  • Study on Fruquintinib and Tislelizumab for Patients with Metastatic Colorectal Cancer Without Liver Metastases

    Recruiting

    1 1 1
    Investigated drugs:
    Austria Germany

Glossary

  • Angiogenesis: The process of forming new blood vessels. In cancer, tumors promote angiogenesis to supply themselves with oxygen and nutrients needed for growth. Fruquintinib works by inhibiting this process.
  • BRAF: A gene that makes a protein called B-Raf, which is involved in sending signals in cells that direct cell growth. Some colorectal cancer trials with fruquintinib focus on patients with wild-type (normal) BRAF status.
  • Complete Response (CR): The disappearance of all signs of cancer in response to treatment. This does not always mean the cancer is cured.
  • Disease Control Rate (DCR): The percentage of patients with a complete response, partial response, or stable disease after treatment. This is a measure of how well a treatment prevents cancer from growing or spreading.
  • Duration of Response (DoR): The length of time from when a tumor starts responding to treatment until it begins to grow again.
  • FOLFIRI: A chemotherapy regimen containing folinic acid, fluorouracil (5-FU), and irinotecan. It's often combined with targeted therapies like fruquintinib in clinical trials.
  • FOLFOX: A chemotherapy regimen containing folinic acid, fluorouracil (5-FU), and oxaliplatin. It's frequently studied in combination with fruquintinib for colorectal cancer.
  • Metastatic: Cancer that has spread from its original site to other parts of the body, creating secondary tumors.
  • MSS (Microsatellite Stability): A characteristic of tumors with normal DNA repair mechanisms. Most colorectal cancers (about 85%) are MSS type, which typically respond less well to immunotherapy alone than MSI-high tumors.
  • Objective Response Rate (ORR): The proportion of patients with a reduction in tumor size of a predefined amount and for a minimum time period. It includes both complete and partial responses.
  • Overall Survival (OS): The length of time from either the date of diagnosis or the start of treatment that patients diagnosed with the disease are still alive.
  • Palmar-Plantar Erythrodysesthesia: Also known as hand-foot syndrome, this is a side effect of some cancer treatments, including fruquintinib, causing redness, swelling, and pain in the palms of the hands and soles of the feet.
  • Partial Response (PR): A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment. Typically defined as at least a 30% decrease in tumor size.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and excreted by the body. Many fruquintinib trials include PK assessments to understand how the drug behaves in the body.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening. This is a common primary endpoint in fruquintinib clinical trials.
  • Proteinuria: The presence of excess protein in the urine, which can be a side effect of treatments that target blood vessels like fruquintinib.
  • RECIST (Response Evaluation Criteria in Solid Tumors): A set of rules used to measure how well a cancer patient responds to treatment. It defines when tumors shrink, stay the same, or grow during treatment.
  • Refractory Cancer: Cancer that does not respond to treatment. Many fruquintinib trials focus on patients with refractory cancer who have already tried standard therapies.
  • Stable Disease (SD): Cancer that is neither growing nor shrinking. The tumor has not decreased enough to qualify as a partial response or increased enough to qualify as progressive disease.
  • Time to Progression (TTP): The length of time from the start of treatment until the cancer starts growing again.
  • Tumor Regression Grade (TRG): A system used to categorize how well a tumor has responded to treatment, based on the amount of living cancer cells versus dead tissue or scar tissue.
  • Tyrosine Kinase Inhibitor (TKI): A type of targeted therapy that blocks specific enzymes called tyrosine kinases, which are involved in cancer cell growth and survival. Fruquintinib is a tyrosine kinase inhibitor that specifically targets VEGFRs.
  • VEGFR (Vascular Endothelial Growth Factor Receptor): A family of receptors (VEGFR-1, -2, and -3) that play key roles in the formation of new blood vessels. Fruquintinib selectively targets these receptors to block tumor blood supply.

References

  1. https://clinicaltrials.gov/study/NCT01645215
  2. https://clinicaltrials.gov/study/NCT03251378
  3. https://clinicaltrials.gov/study/NCT06202599
  4. https://clinicaltrials.gov/study/NCT07150403
  5. https://clinicaltrials.gov/study/NCT03684967
  6. https://clinicaltrials.gov/study/NCT06774222
  7. https://clinicaltrials.gov/study/NCT06446154
  8. https://clinicaltrials.gov/study/NCT05522231
  9. https://clinicaltrials.gov/study/NCT04156958
  10. https://clinicaltrials.gov/study/NCT05257122
  11. https://clinicaltrials.gov/study/NCT05142631
  12. https://clinicaltrials.gov/study/NCT03903705
  13. https://clinicaltrials.gov/study/NCT05025631
  14. https://clinicaltrials.gov/study/NCT01955304
  15. https://clinicaltrials.gov/study/NCT06562543
  16. https://clinicaltrials.gov/study/NCT07042685
  17. https://clinicaltrials.gov/study/NCT04582981
  18. https://clinicaltrials.gov/study/NCT04296019
  19. https://clinicaltrials.gov/study/NCT05216367
  20. https://clinicaltrials.gov/study/NCT05216354
  21. https://clinicaltrials.gov/study/NCT06018714
  22. https://clinicaltrials.gov/study/NCT04645940